Solantra (ivermectin) creme 1%

Directions for use and doses

For external use only.

Apply Solantra cream once a day every day throughout the entire course of treatment - up to 4 months. If necessary, the course of treatment can be repeated.

If there is no improvement after 3 months of using the drug, treatment should be discontinued.

Apply a small amount of cream (the size of a pea) to the skin of each of the five areas of the face: forehead, chin, nose and cheeks. Distribute the drug in a thin layer over the entire face, avoiding contact with the eyes, lips and mucous membranes.

Solantra should only be applied to the face.

In patients with impaired renal function and elderly patients, no dose adjustment is required.Indications

Treatment of inflammatory skin lesions with rosacea (papulopustular form) in adult patients.

Compound

1 g of cream contains:

Active ingredient: ivermectin 10.0 mg.

Excipients: glycerol 40.0 mg, isopropyl palmitate 40.0 mg, carbomer copolymer type B 2.0 mg, dimethicone 20 Cst 5.0 mg, disodium edetate 0.5 mg, citric acid monohydrate 0.5 mg, cetyl alcohol 35 .0 mg, stearic alcohol 25.0 mg, macrogol cetostealyl ether 30.0 mg, sorbitan stearate 20.0 mg, methyl parahydroxybenzoate 2.0 mg, propyl parahydroxybenzoate 1.0 mg, phenoxyethanol 10.0 mg, propylene glycol 20.0 mg, oleyl alcohol 20.0 mg, sodium hydroxide solution 10% to pH 6.3±0.3, purified water up to 1000 mg.Contraindications

- Hypersensitivity to the active substance or any other component of the drug;

- pregnancy;

- period of breastfeeding;

- children under 18 years of age (the safety and effectiveness of the drug for this age category have not been studied).

Carefully:

Liver dysfunction.

Pregnancy and lactation:

Pregnancy

There are limited or no data on the use of ivermectin in pregnant women. Reproductive toxicity studies following oral administration of ivermectin have shown that the drug has teratogenic potential in rats and rabbits, but due to low systemic exposure when applied topically at the recommended dosage, the drug has a low risk of fetotoxicity in humans. The use of Solantra during pregnancy is not recommended.

Breastfeeding period

Following oral administration, low concentrations of ivermectin are excreted into breast milk. When the drug is used externally, the release of ivermectin into breast milk has not been studied. Pharmacokinetic and toxicological data obtained from animal studies also indicate the release of ivermectin into breast milk. A risk to the nursing infant cannot be excluded. If it is necessary to use the drug, you should consult your doctor to decide whether to stop breastfeeding.

special instructions

The medicinal product contains:

- cetyl alcohol and stearyl alcohol, which can cause local skin reactions (for example, contact dermatitis),

- methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216), which can cause allergic reactions (including delayed ones),

- propylene glycol, which may cause skin irritation.

After applying the medicine, you must wash your hands.

After the drug has dried, cosmetics can be applied.

Impact on the ability to drive vehicles. Wed and fur.:

Solantra does not affect or only slightly affects the ability to drive vehicles and operate machinery.